teligiline

Teligiline is a pharmaceutical agent currently under clinical investigation for its utility in anesthesia and pain management. Specifically, it is being evaluated for its ability to suppress the physiological and motor responses associated with laryngeal mask airway (LMA) insertion in elderly patients undergoing surgery. The drug is typically administered intravenously to achieve rapid onset of action, aiming to mitigate procedural pain and agitation. Clinical studies, such as those conducted at The First People’s Hospital of Lianyungang, focus on determining the 90% effective dose (ED90) and assessing the safety profile and perioperative vital sign stability in geriatric populations.

Other names

teligiline